title: Autologous HSCT for advanced MS: is the glass half-empty or really half-full?
authors.forename: Richard A
authors.initials: RA
authors.lastname: Nash
authors.forename: Olaf
authors.initials: O
authors.lastname: Stuve
authors.forename: James D
authors.initials: JD
authors.lastname: Bowen
authors.forename: Elliot M
authors.initials: EM
authors.lastname: Frohman
authors.forename: Linda M
authors.initials: LM
authors.lastname: Griffith
authors.forename: George J
authors.initials: GJ
authors.lastname: Hutton
authors.forename: George H
authors.initials: GH
authors.lastname: Kraft
authors.forename: Uday
authors.initials: U
authors.lastname: Popat
authors.forename: Michael K
authors.initials: MK
authors.lastname: Racke
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Muraro
mesh_terms: D001344:Autopsy; D001369:Axons / Q000473:pathology; D001706:Biopsy; D001921:Brain / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D009103:Multiple Sclerosis / Q000628:therapy*; D017211:Treatment Failure
chemical_list: D007166:Immunosuppressive Agents